Polyamidoamine-based nanovector for the efficient delivery of methotrexate to U87 glioma cells

Natalia Ortiz, Pilar A. Vásquez, Felipe Vidal, Carola F. Díaz, José L. Guzmán, Verónica A. Jiménez, Joel B. Alderete

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

The purpose of this study was to design a polyamidoamine (PAMAM)-based nanovector for the efficient delivery of methotrexate to U87 glioma cells. To this end, 0-100% acetylated PAMAM dendrimers of the fourth generation were synthesized and evaluated using drug encapsulation measurements, molecular dynamics simulations, neurotoxicity assays and neuronal internalization experiments. The best system was tested as a nanovector for methotrexate delivery to U87 glioma cells. The authors found that 25% acetylated PAMAM dendrimers of the fourth-generation combine low intrinsic toxicity, large drug complexation capacity and efficient internalization into hippocampal neurons. Nanovector complexation enhances the cytotoxic response of methotrexate against U87 glioma cells compared with free drug solutions. In conclusion, 25% acetylated PAMAM dendrimers of the fourth-generation increase drug uptake by glioma cells and thereby act as efficient nanovectors for methotrexate delivery.

Original languageEnglish
Pages (from-to)2771-2784
Number of pages14
JournalNanomedicine (London, England)
Volume15
Issue number28
DOIs
Publication statusPublished - 1 Dec 2020

Keywords

  • dendrimer-based delivery
  • glioma targeting
  • methotrexate
  • nanovector

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)

Fingerprint

Dive into the research topics of 'Polyamidoamine-based nanovector for the efficient delivery of methotrexate to U87 glioma cells'. Together they form a unique fingerprint.

Cite this